Starboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best pipeline" ever.
Activist hedge fund Starboard has taken a stake in drug giant Pfizer. Starboard execs met with company officials last week to outline their complaints.
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential for growth in Kenvue, and more.
Hedge funds managed by Israel Englander and Ken Griffin both scooped up shares in a troubled pharmaceutical stock last quarter.
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
Pfizer (PFE) reachead $28.93 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
Income investors have both good and not-so-good options in the healthcare sector.
Pfizer's deep valuation and large dividend yield make it an attractive investment, despite potential distractions from activist investors. The focus should remain on existing cost realignment plans and pipeline investments to ensure positive financial returns for shareholders. The stock only trades at 10x forward EPS targets.
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Pfizer's high dividend yield and robust pipeline could offer significant returns for patient investors.
Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie Hyman and Josh Lipton to break down how to play biotech and pharmaceutical stocks. Johnson & Johnson reports earnings on Tuesday, which Shibutani says “typically kicks off earnings season for healthcare, but also for the large-cap pharmas.